“Schizophrenia Pipeline Insight” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Schizophrenia market. A detailed picture of the Schizophrenia pipeline landscape is provided, which includes the disease overview and Schizophrenia treatment guidelines.
Some of the key highlights from the Schizophrenia Pipeline report:
Request for Free Sample Report: https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight
Schizophrenia Pipeline Analysis: Drug Profile
SEP-363856 is a TAAR1 agonist with 5-HT1A agonist activity. The therapy is under trial for the treatment of schizophrenia and other psychiatric conditions. Sunovion is running a global Phase III development program for schizophrenia (DIAMOND) with additional indications under consideration.
NCT04109950: Study SEP361-301 or Study SEP361-302, “an open-label extension study to assess the safety and tolerability of SEP-363856 in subjects with Schizophrenia”, is currently in the recruiting stage with an estimated enrollment of 555 participants and expected to be completed in November 2022.
NCT04072354: Sunovion initiated a phase III trial titled “A randomized, double-blind, parallel-group, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia”, which is expected to be completed in September 2021.
Doria is a monthly intramuscular injection that does not require loading doses or concurrent oral risperidone. It is a new long-acting injectable (LAI) intramuscular formulation of risperidone, for monthly administration without oral supplementation. As researchers suggest that the intramuscular route of administration is more effective compared to oral, hence Doria is expected to generate the highest market share compared to other therapies. It is in the preregistration stage for Schizophrenia in the USA.
Roluperidone is meant to block a specific subtype of serotonin receptor called 5-HT2A. When 5-HT2A is blocked, certain symptoms of schizophrenia, such as hallucinations, delusions, agitation, and thought and movement disorders, as well as the side effects associated with antipsychotic treatments, can be minimized. Additionally, blocking 5-HT2A promotes slow-wave sleep, a sleep stage often disrupted in patients with schizophrenia. It is currently in phase 3 of clinical trials and in December 2020 Minerva Neurosciences announces its intention to request a pre-NDA meeting with the US FDA for planned NDA submission of Roluperidone for Schizophrenia.
Dive deeper to know more @ Schizophrenia therapeutics and drugs pipeline
Key Pipeline Therapies along with Schizophrenia Companies
Got queries? Reach out for more information @ Schizophrenia Drug Pipeline Assessment
Scope of the Report
Table of contents
1. Report Introduction
2. Schizophrenia
3. Schizophrenia Current Treatment Patterns
3.1. Schizophrenia Treatment Guidelines
4. Schizophrenia – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Schizophrenia Late Stage Products (Phase-III)
7. Schizophrenia Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Schizophrenia Discontinued Products
13. Schizophrenia Product Profiles
14. Schizophrenia Key Companies
15. Schizophrenia Key Products
16. Dormant and Discontinued Products
17. Schizophrenia Unmet Needs
18. Schizophrenia Future Perspectives
19. Schizophrenia Analyst Review
20. Appendix
21. Report Methodology
Get in touch with our Business Executive @ BK virus (BKV) Infection Pipeline Trends and Futuristic Outlook to learn more about the domain.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight